ANSOLYSEN
Clinical safety rating
cautionComprehensive clinical and safety monograph for ANSOLYSEN (ANSOLYSEN).
Pentolinium (ANSOLYSEN) is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at autonomic ganglia, blocking both sympathetic and parasympathetic transmission.
| Metabolism | Hepatic metabolism; excreted primarily unchanged in urine. |
| Excretion | Renal excretion predominates (approximately 70-80% as unchanged drug via glomerular filtration; remainder as metabolites). Biliary/fecal elimination accounts for <10%. |
| Half-life | Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 24-48 hours in renal impairment, necessitating dose adjustment. |
| Protein binding | Approximately 30-40% bound to serum albumin; binding is reversible and concentration-independent. |
| Volume of Distribution | Vd is 0.5-1.0 L/kg indicating extensive tissue distribution (primarily in highly perfused organs), with little accumulation in fat. |
| Bioavailability | Oral bioavailability is low (10-25%) due to significant first-pass metabolism; subcutaneous bioavailability >90%; intramuscular near 90%; intravenous 100%. |
| Onset of Action | Intravenous: 1-2 minutes (immediate effect); intramuscular: 5-15 minutes (peak effect at 15-30 minutes); subcutaneous: 10-20 minutes; oral: 1-2 hours. |
| Duration of Action | Intravenous: 15-30 minutes; intramuscular/subcutaneous: 2-4 hours; oral: 6-12 hours. Duration correlates with blood pressure reduction and orthostatic effects. |
| Molecular Weight | 544.53 |
Initial: 2.5 mg intramuscularly or subcutaneously every 6 hours, gradually increased to 5-20 mg every 6 hours as needed.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment. For GFR 10-50 mL/min: reduce dose by 50% and increase dosing interval. For GFR <10 mL/min: avoid use. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment due to potential for increased toxicity. |
| Pediatric use | Not established; safety and efficacy in children have not been determined. |
| Geriatric use | Use with caution; start at lower end of dosing range due to increased sensitivity and risk of hypotension and falls. |
| 1st trimester | Contraindicated; pentolinium (ANSOLYSEN) is a ganglion blocker that may cause fetal hypotension and hypoxia. Animal studies suggest teratogenic potential, but human data are lacking. |
| 2nd trimester | Contraindicated; sustained maternal hypotension can reduce uteroplacental perfusion, leading to fetal growth restriction or distress. |
| 3rd trimester | Contraindicated; may induce neonatal hypotension, respiratory depression, and meconium ileus. Avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for ANSOLYSEN (ANSOLYSEN).
| Placental transfer | Crosses the placenta; lipid-soluble quaternary ammonium compound capable of achieving fetal concentrations similar to maternal levels. |
| Breastfeeding | Excreted into breast milk; potential for ganglionic blockade in the infant, causing hypotension, gastrointestinal disturbances, and respiratory depression. Avoid breastfeeding while on this drug. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | First trimester: Potential for teratogenic effects based on animal studies; human data limited. Second and third trimesters: Risk of fetal bradycardia, hypothermia, and respiratory depression due to ganglionic blockade. May cause neonatal hypotension if used near term. |
| Fetal Monitoring | Maternal: frequent blood pressure monitoring, heart rate, and signs of orthostatic hypotension. Fetal: ultrasound for growth and amniotic fluid volume; fetal heart rate monitoring if used in third trimester. |
| Fertility Effects | May impair fertility in both males and females due to autonomic effects; oligospermia reported in males. Reversible upon discontinuation. |
■ FDA Black Box Warning
None specified in standard references.
| Serious Effects |
Hypersensitivity to pentoliniumSevere hypotensionCoronary insufficiencyCerebrovascular insufficiencyGlaucomaPyloric stenosisRenal insufficiency
| Precautions | Severe hypotension, Paralytic ileus, Bladder atony, Pupillary dilatation and photophobia, Loss of accommodation, Syncope and precipitating angina, Interstitial pulmonary edema and fibrosis |
| Food/Dietary | Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) as ganglionic blockers may potentiate pressor responses. Limit salt intake to manage blood pressure. Grapefruit juice may alter drug metabolism? No known significant interaction; however, general caution with high-tyramine foods is advised. |
| Clinical Pearls | ANSOLYSEN (mecamylamine) is a secondary amine and a ganglionic blocker used in severe hypertension. Due to its narrow therapeutic index and risk of paralytic ileus, it is rarely used today. Monitor for orthostatic hypotension, urinary retention, and constipation. Avoid in patients with pyloric stenosis, recent myocardial infarction, or glaucoma. Use with caution in renal impairment as drug is renally excreted. |
| Patient Advice | Take exactly as prescribed; do not double doses if missed. · Rise slowly from lying or sitting to prevent dizziness. · Avoid alcohol and hot baths/saunas as they may worsen hypotension. · Report severe constipation, difficulty urinating, or blurred vision immediately. · Do not discontinue abruptly; taper under medical supervision. |
Loading safety data…